COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #114
Source   PDF   Share   Tweet
See all 182 studies
Late treatment study
Fried et al., Clinical Infectious Disease, doi:10.1093/cid/ciaa1268 (Peer Reviewed)
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States
Database analysis of 11,721 hospitalized patients, 4,232 on HC Q. Strong evidence for confounding by indication and compassionate use of HC Q. 24.9% of HC Q patients were on mechanical ventilation versus 12.2% control. Ventilation mortality was 70.5% versus 11.6%.
This study does not adjust for the differences in comorbid conditions and disease severity, and therefore does not make a conclusion. Unadjusted HC Q mortality was 24.8% versus control 19.6%. Adjusting for ventilation only gives us 17.7% HC Q versus 19.6% control (adjusting the HC Q group to have the same proportion of ventilation patients), RR 0.90. Hopefully authors can do a full adjustment analysis. Comorbidities may favor control, while patients remaining in the hospital (5.3%) may favor HC Q (other studies show faster resolution for HC Q patients).
Data inconsistencies have been found in this study, for example 99.4% of patients treated with HC Q were treated in urban hospitals, compared to 65% of untreated patients (Supplemental Table 3), while patients are distributed in a more balanced manner between teaching or not-teaching hospitals, as well as in the most urbanized (Northeast) and less urbanized (Midwest) regions of the United States [1].
death, ↑27.0%, p<0.001
Source   PDF   Share   Tweet
See all 182 studies
Please send us corrections, updates, or comments.